Introduction
Lupus nephritis (LN) is one of the most severe manifestations of systemic lupus erythematosus (SLE). The clinical course ranges from asymptomatic urinary occult blood to nephrotic syndrome or acute kidney injury. LN is associated with considerable morbidity and mortality [1] .
Cytokines play a key role in disease initiation and progression; in fact, in the kidney, immune complex deposition activates mesangial cells. Once activated by immune complexes and/or autoantibodies, renal resident cells secrete cytokines that may further amplify inflammatory processes [2] .
Case Report
A 42-year-old woman presented with LN due to SLE. She was first admitted to the Nephrology and Dialysis Department of San Benedetto del Tronto Hospital in 2003 due to the detection of urinary abnormalities and increased creatinine (up to 3 mg/dl). She had a presumptive diagnosis of psoriatic arthritis since 2002. An in-depth diagnostic and biopsy analysis led to the definitive diagnosis of SLE with LN [medical report of optical microscopy ascribable to LN (class II according to the WHO) with activities 7 and stage 0, medical report of electronic microscopy compatible with the diagnosis of LN (class III according to the WHO) and antiphospholipid syndrome (APS) with presence of lupus anticoagulant antibodies and anticardiolipin antibodies].
Subsequently, the patient was subjected to treatment with induction immunosuppressive therapy with cyclophosphamide and prednisone for periodic exacerbation of basic immunological disease when she presented with proteinuria, high levels of inflammatory markers and abnormal liver function. She also had periods of clinical stability (characterized by a general improvement with normalization of liver and kidney function and remission of proteinuria) with mycophenolate mofetil.
These cycles continued until 2006, when she presented with hemolytic-uremic syndrome with severe hypertension (260/130 mm Hg), grand mal and oliguria. She was then started on hemodialysis due to the rapid deterioration of renal function which, despite a new cycle of induction therapy, produced end-stage renal disease and required chronic hemodialysis treatment.
During the initial hemodialysis period, she continued therapy with mycophenolic acid and prednisone. Symptoms and signs of systemic disease activity persisted and included arthralgia, asthenia, episodic fever, maculopapular rash, elevated erythrocyte sedimentation rate and leuko-thrombocytopenia. Although the patient underwent 1-4 plasma exchanges (PEX) per month, the combination of PEX with methylprednisolone bolus and IgG admin-istration achieved only limited improvements of arthralgia and cutaneous manifestations (necrotic-like skin lesions).
During the last 2 years, the patient has been started on a new hemodiafiltration technique, hemodiafiltration with endogenous reinfusion dialysis treatment, which uses the super-high-flux membrane Synclear 02 (SUPRA treatment) coupled to an adsorbent cartridge.
Fever and joint pain were significantly reduced as early as in the first week of treatment. During the following few months, skin manifestations were significantly reduced and the patient reported an improved quality of life (QoL). After starting SUPRA (3 times weekly for 4 h per session), the patient no longer needed any additional PEX treatment. Prednisone and immunosuppressors were gradually reduced and eventually discontinued since the improvement of symptoms suggested a trend towards systemic remission.
After 6 months of prednisone and mycophenolic acid therapy suspension, there were no further events to be considered as an expression of SLE activity. The patient has reported an improvement in asthenia and has not experienced any further episodes of fever or arthralgia. She currently continues using the SUPRA technique.
Laboratory analysis showed an improvement in leuko-thrombocytopenia; however, the patient still has a persistent elevation of the erythrocyte sedimentation rate, low levels of C3 and C4 complement and a moderate increase in IgG and antinuclear antibody.
The QoL of the patient was analyzed by the RAND 36-Item Health Survey before starting and 3 weeks after SUPRA treatment. The resulting scores illustrate how the SUPRA treatment led to an improvement in QoL. In particular, physical functioning, energy/fatigue and pain scores increased from 20 to 90, 15 to 70 and 22.5 to 67.5, respectively.
Although the timing between the beginning of SUPRA treatment and the complete remission of SLE symptoms may suggest an association between the SUPRA therapy and clinical improvement, we cannot exclude that there was a spontaneous remission of systemic disease, as known to occur sometimes in dialysis patients. This case, moreover, places further emphasis on the role of inflammatory mediators in SLE symptom manifestations and the therapeutic potential of SUPRA treatment.
Discussion
LN increases the morbidity and mortality of patients with SLE. SLE patients commonly have increased levels of IL-6 and IL-10, which further increase in patients with active disease.
Jacob and Stohl [3] have rated four cytokines [IL-6, tumor necrosis factor α (TNF-α), IFN-α and B-lymphocyte stimulator (BLyS)] as therapeutic targets in SLE. This study shows that the reduction of these proinflammatory cytokines has a beneficial effect on the course of the disease. To date, the potential of cytokines as therapeutic targets for lupus has been shown both by a BLyS inhibitor (belimumab, recently approved by the United States Food and Drug Administration as a treatment for SLE) and by ongoing trials on other cytokine inhibitors [4] .
In particular, IL-6 is a multifunctional cytokine produced in response to inflammatory stimuli, including those mediated by IL-1 and TNF-α, with key roles in the regulation of the immune response to infections. IL-6 was indicated as a potent stimulator of the differentiation and activation of lymphoid and myeloid cells and the production of acute-phase proteins in the liver. IL-6 is also a key regulator of many other cellular processes, including erythropoiesis, neuronal cell differentiation and bone metabolism. There is an inverse correlation between levels of IL-6 and hemoglobin levels in patients with SLE.
Hemodiafiltration with on-line endogenous reinfusion (HFR-SUPRA treatment) is a dialytic method which combines the processes of diffusion, convection and adsorption. The performance of this system is linked to the optimal combination of the membrane permeability and cartridge resin bed [5] .
It has been demonstrated that the sorbent cartridge has a high affinity for several uremic toxins and middle molecules, such as β2-microglobulin, homocysteine, angiogenin, leptin, parathormone and some chemokines and cytokines. In contrast, the cartridge does not retain bicarbonate, amino acids and hydrosoluble vitamins. Other solutes, such as urea, creatinine, uric acid, Na+, K+, Ca2+, phosphate and bicarbonate, which are not adsorbed by the cartridge, are cleared, by diffusion, in the second chamber of the filter [6] [7] [8] .
In addition to cytokine removal information, high-performance liquid chromatography coupled with quadrupole time-of-flight mass spectrometer (HPLC-QTOF-MS) was used for the identification of proteins in the ultrafiltrate and the species captured by the resin bed (eluted proteins), obtained in a dialysis session of the patient ( fig. 1; table 1 ).
Several biomarker of LN kidney injuries were identified in HPLC-QTOF analysis of eluted proteins, such as retinol-binding protein 4 (RBP4), neutrophil gelatinase-associated lipocalin (NGAL), zinc α-2 glycoprotein (ZA2G) and cystatin-C (CYTC).
Moreover, additional uremic toxins such as serotransferrin (TRFE), α-1-acid glycoprotein (A1AG1), prostaglandin-H2 D-isomerase (PTGDS) and transthyretin (TTHY) were identified. All of these markers are considered, by Varghese et al. [9] , as biomarkers for glomerular disease. Furthermore, Suzuki et al. [10] initiated the validation of TRFE, ceruloplasmin (CERU), A1AG1, PTGDS, albumin and albumin-related fragments as biomarkers for active pediatric LN. Clearly, we identified several fragments of immunoglobulins that are implicated in the etiopathogenesis of SLE.
Another important protein in the pathophysiology of SLE is β-2-glycoprotein 1 (APOH), the principal autoantigen in APS. APS is associated with arterial and venous thrombosis, characterized by up to 30 different autoantibodies [11] . APOH, an abundant plasma phospholipid-binding protein, binds to anionic zwitterionic phospholipids, involved in clotting, but its physiological function is not completely understood [12] .
Last but not least, we found neutrophil defensin 1 (DEF1) among the identified proteins, a member of the α-defensin family. DEF1 -and DEF2 -has antibacterial, fungicide and antiviral activities. Both have antimicrobial activity against Gram-negative and Gram-positive bacteria. Defensins are thought to kill microbes by permeabilizing their plasma membrane [13] .
In addition to exerting direct antimicrobial effects, defensins facilitate and amplify subsequent innate and adaptive immune responses, such as activation and degranulation of mast cells, interleukin and TNF production and maturation of dendritic cells.
Sthoeger et al. [14] have shown that the presence of high serum levels of α-defensin correlates with higher rates of arthritis and renal and dermatological involvement and, in general, the α-defensin levels correlate significantly with disease activity. Thus, when α-defensin levels decreased to the normal range, an improvement in lupus-related manifestations was observed.
If compared with patients with low α-defensin levels, most SLE patients with high levels of DEF1 were treated with corticosteroids. Probably, the elimination of this protein from blood could explain the reduction in corticosteroid administration [14] .
The results of this study demonstrate that styrenic resin retained several proteins implicated in the LN pathogenesis. This means that SUPRA treatment is a dialysis method that reduces inflammatory status, uremic toxin level and could improve LN prognosis may- 
